Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

About this update from Climb Bio, Inc.

[{"type":"image","alt":"Climb Bio, Inc.","displaySize":"","headline":null,"caption":"Climb Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/upR1wQHp9TCZxvAhULaG8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c","width":300,"height":300}},"lazy":false},{"type":"text","content":"WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.","length":239,"tagName":"p"},{"type":"text","content":"24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast: Click here","length":169,"tagName":"p"},{"type":"text","content":"About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.","length":486,"tagName":"p"},{"type":"text","content":"InvestorsChris Brinzey ICR [email protected]","length":84,"tagName":"p"},{"type":"text","content":"MediaJon YuICR [email protected]","length":65,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]

More updates from Climb Bio, Inc.